Are you over 18 and want to see adult content?
More Annotations
![A complete backup of thesportsrush.com/pk-w-vs-tl-w-dream11-prediction-pakistan-women-vs-thailand-women-best-dream-11-team-for-i](https://www.archivebay.com/archive2/2051085f-0847-4937-925b-60757af2bf45.png)
A complete backup of thesportsrush.com/pk-w-vs-tl-w-dream11-prediction-pakistan-women-vs-thailand-women-best-dream-11-team-for-i
Are you over 18 and want to see adult content?
![A complete backup of www.voici.fr/news-people/actu-people/isabelle-morini-bosc-tpmp-revele-avoir-ete-violee-et-avoir-subi-des-at](https://www.archivebay.com/archive2/4fa89107-85e4-4765-86da-1f95bcc21b8b.png)
A complete backup of www.voici.fr/news-people/actu-people/isabelle-morini-bosc-tpmp-revele-avoir-ete-violee-et-avoir-subi-des-at
Are you over 18 and want to see adult content?
![A complete backup of www.ggilbo.com/news/articleView.html?idxno=749629](https://www.archivebay.com/archive2/0ccdea8a-f4fb-4c3e-9eec-5b9048ad4c5b.png)
A complete backup of www.ggilbo.com/news/articleView.html?idxno=749629
Are you over 18 and want to see adult content?
Favourite Annotations
![MAYAMAGIK | Christian Koehlert Media Artworks & Storytelling](https://www.archivebay.com/archive/bdb193e9-9e3a-4282-bd75-a6dd6436a004.png)
MAYAMAGIK | Christian Koehlert Media Artworks & Storytelling
Are you over 18 and want to see adult content?
![A complete backup of tananachiefs.org](https://www.archivebay.com/archive/aff6f5f1-3988-4ef6-a6c0-83cb872d28c0.png)
A complete backup of tananachiefs.org
Are you over 18 and want to see adult content?
![شرکت توربین توان گستر ایرانیان – گام به گام تکنولوژی روز دنیا](https://www.archivebay.com/archive/8ddac1de-4926-4764-a4d4-e37a4da266bc.png)
شرکت توربین توان گستر ایرانیان – گام به گام تکنولوژی روز دنیا
Are you over 18 and want to see adult content?
![Best Online Shopping Store for Electronics, Fashion, Home Improvement & More in Kuwait](https://www.archivebay.com/archive/2909cac7-4c58-489f-a73e-8b8fc3566eb5.png)
Best Online Shopping Store for Electronics, Fashion, Home Improvement & More in Kuwait
Are you over 18 and want to see adult content?
![SCHWARZPLAN.eu - Lageplan Downloads als Vektor- & CAD-Plan](https://www.archivebay.com/archive/616e232a-7edc-422e-ae6c-76b39d4e4eee.png)
SCHWARZPLAN.eu - Lageplan Downloads als Vektor- & CAD-Plan
Are you over 18 and want to see adult content?
![WordPress.com — Get a Free Blog Here](https://www.archivebay.com/archive/c32f9e2c-0835-4c13-9589-55d96561998c.png)
WordPress.com — Get a Free Blog Here
Are you over 18 and want to see adult content?
![Marketing Agency St. Louis | Branding, Web Design, Content](https://www.archivebay.com/archive/7d23991a-0711-42cb-b1fb-a6be95d34836.png)
Marketing Agency St. Louis | Branding, Web Design, Content
Are you over 18 and want to see adult content?
Text
COVID-19 AND CML
At this time, based on best available information, patients with chronic myeloid leukemia (CML) are considered appropriate to receive vaccines against COVID-19. While rare special circumstances may exist, most patients, whether early in treatment, in ongoing response, in deep remission, or off therapy having pursued ‘treatment freeremission
COVID-19 AND MYELODYSPLASTIC SYNDROMES There are no data indicating that patients with MDS are more likely to contract COVID-19 than patients with healthy bone marrows. Studies from Italy, the US, UK, and China indicate a higher mortality rate from COVID-19 among patients with a history of cancer, including hematological malignancy, compared to those without such a history.COVID-19 AND CLL
Phone 202-776-0544 Toll Free 866-828-1231 Fax 202-776-0545 COVID-19 AND MULTIPLE MYELOMA Multiple myeloma patients with active disease need treatment to avoid morbidity and mortality, despite the COVID-19 pandemic; however, treatment can be individualized to limit additional exposure to COVID-19. For example, we recommend starting triplet therapy with bortezomib, lenalidomide and dexamethasone (RVD) for 6- 12 cyclesfollowed by
COVID-19 AND ITP
Severe COVID-19 infection is accompanied by a risk of thrombosis, but there is no evidence that this risk is increased by raising platelet counts to hemostatic levels or exacerbated by any specific form of ITP management, even splenectomy and thrombopoietic (TPO) agents which may be associated with some excess thrombosis in non-COVID ITP settings. HEMATOLOGY REVIEW SERIES The ASH Hematology Review Series is designed for fellows preparing to take the internal medicine hematology certification exam or those desiring a comprehensive update of hematology standards of care. This series provides a free review of hematology patterned after the American Board of Internal Medicine (ABIM) Certification ExaminationBlueprint.
COVID-19 AND PULMONARY EMBOLISM An elevated D-dimer level does not confirm a diagnosis of PE/DVT in a patient with COVID-19 because the elevated D-dimer may result from the COVID-19 infection or other causes. If possible, CTPA and/or bilateral CUS should be performed to investigate for PE/DVT. It is important to determine if there are any new clinical findings that indicate COVID-19 AND THALASSEMIA Luspatercept has been approved for adults with transfusion dependent beta thalassemia and has been shown to significantly reduce transfusion burden in this population. No data are available to date on luspatercept and COVID-19. If patients are currently taking luspatercept, there are no theoretical reasons to stop treatment. DIAGNOSIS AND MANAGEMENT OF SUSPECTED VACCINE-INDUCED Austria/Germany Norway UK Number of patients 11 5 23 Onset post vaccine, days 5-16 7-10 6-24 Age, years 22-49 32-54 21-77 Sex: male 21 9 female 9 4 14
BLOOD HERISHANU COVID VACCINE AND CLL Blood (www.bloodjournal.org), the most cited peer-reviewed publication in the field of hematology, is available weekly in print and online. Blood is a journal of the American Society of Hematology (ASH) (www.hematology.org).. Contact: Leah Enser, American Society of Hematology lenser@hematology.org; 202-552-4927COVID-19 AND CML
At this time, based on best available information, patients with chronic myeloid leukemia (CML) are considered appropriate to receive vaccines against COVID-19. While rare special circumstances may exist, most patients, whether early in treatment, in ongoing response, in deep remission, or off therapy having pursued ‘treatment freeremission
COVID-19 AND MYELODYSPLASTIC SYNDROMES There are no data indicating that patients with MDS are more likely to contract COVID-19 than patients with healthy bone marrows. Studies from Italy, the US, UK, and China indicate a higher mortality rate from COVID-19 among patients with a history of cancer, including hematological malignancy, compared to those without such a history.COVID-19 AND CLL
Phone 202-776-0544 Toll Free 866-828-1231 Fax 202-776-0545 COVID-19 AND MULTIPLE MYELOMA Multiple myeloma patients with active disease need treatment to avoid morbidity and mortality, despite the COVID-19 pandemic; however, treatment can be individualized to limit additional exposure to COVID-19. For example, we recommend starting triplet therapy with bortezomib, lenalidomide and dexamethasone (RVD) for 6- 12 cyclesfollowed by
COVID-19 AND ITP
Severe COVID-19 infection is accompanied by a risk of thrombosis, but there is no evidence that this risk is increased by raising platelet counts to hemostatic levels or exacerbated by any specific form of ITP management, even splenectomy and thrombopoietic (TPO) agents which may be associated with some excess thrombosis in non-COVID ITP settings. HEMATOLOGY REVIEW SERIES The ASH Hematology Review Series is designed for fellows preparing to take the internal medicine hematology certification exam or those desiring a comprehensive update of hematology standards of care. This series provides a free review of hematology patterned after the American Board of Internal Medicine (ABIM) Certification ExaminationBlueprint.
COVID-19 AND PULMONARY EMBOLISM An elevated D-dimer level does not confirm a diagnosis of PE/DVT in a patient with COVID-19 because the elevated D-dimer may result from the COVID-19 infection or other causes. If possible, CTPA and/or bilateral CUS should be performed to investigate for PE/DVT. It is important to determine if there are any new clinical findings that indicate COVID-19 AND THALASSEMIA Luspatercept has been approved for adults with transfusion dependent beta thalassemia and has been shown to significantly reduce transfusion burden in this population. No data are available to date on luspatercept and COVID-19. If patients are currently taking luspatercept, there are no theoretical reasons to stop treatment. DIAGNOSIS AND MANAGEMENT OF SUSPECTED VACCINE-INDUCED Austria/Germany Norway UK Number of patients 11 5 23 Onset post vaccine, days 5-16 7-10 6-24 Age, years 22-49 32-54 21-77 Sex: male 21 9 female 9 4 14
THROMBOSIS WITH THROMBOCYTOPENIA SYNDROME Shortness of breath. Leg pain or swelling. Petechiae, easy bruising, or bleeding. If TTS is suspected, perform immediate CBC with platelet count and imaging for thrombosis based on symptoms. If thrombocytopenia or thrombosis are present, recommend urgent consultation from hematologist with expertise in hemostasis. COVID-19 AND MYELOPROLIFERATIVE NEOPLASMS The risks of bleeding on anticoagulation are higher in MPN patients, particularly in those with prior hemorrhages or extreme thrombocytosis or thrombocytopenia. The risk is even higher in MPN patients with hepatic failure (INR >1.5) or severe renal failure (filtration rate < 30ml/min per m2). We strongly recommend that COVID-19 infected andCOVID-19 AND TTP
Patients with cTTP that become infected with COVID-19 similarly would be at increased risk for an acute TTP episode as a result of the infection and the secondary inflammatory state. Patients with cTTP and COVID-19 infection should be monitored carefully for hemolysis. cTTP patients with COVID-19 may need an intensified plasma infusionschedule
COVID-19 AND HODGKIN LYMPHOMA The COVID-19 PANDEMIC: A Rapid Global response for Children with Cancer from SIOP, COG, SIOP-E, SIOP-PODC, IPSO, PROS, CCI and St Jude Global. Authorea. April 25, 2020. DOI: 10.22541/au.158777298.87289192. Clift, Coupland CAC, Keogh RH et al. Living risk prediction algorithm (QCOVIDk) for risk of hospital admission and mortality from COVID-19 AND THALASSEMIA Luspatercept has been approved for adults with transfusion dependent beta thalassemia and has been shown to significantly reduce transfusion burden in this population. No data are available to date on luspatercept and COVID-19. If patients are currently taking luspatercept, there are no theoretical reasons to stop treatment. COVID-19 AND INDOLENT LYMPHOMAS According to one report, the more intensive the therapy, the greater the impact on clinical outcomes from COVID-19. Furthermore, patients with lymphoma may have an increased susceptibility to infection with SARS-CoV-2. Patients should be encouraged to be vaccinated for the flu and cautioned to follow recommendations for reducing risks of LEGENDS IN HEMATOLOGY Legends in Hematology. Many hematologists have been instrumental in the development of ASH and have greatly advanced the field through their numerous contributions. Meet some of these notable leaders profiled as part of ASH's 50th anniversary in 2008 by following the links below to read their profiles and hear their insights about thefield and
ASH VITT MEDIA ADVISORY The American Society of Hematology (ASH) (www.hematology.org) is the world’s largest professional society of hematologists dedicated to furthering the understanding, diagnosis, treatment, and prevention of disorders affecting the blood. For more than 60 years, the Society has led the development of hematology as a discipline by promoting research, patient care, education, training, DIAGNOSIS AND MANAGEMENT OF SUSPECTED VACCINE-INDUCED Austria/Germany Norway UK Number of patients 11 5 23 Onset post vaccine, days 5-16 7-10 6-24 Age, years 22-49 32-54 21-77 Sex: male 21 9 female 9 4 14
PEDIATRIC TO ADULT HEMATOLOGIC CARE TRANSITION Recognizing the need to improve this transition process and to enhance care coordination between practices, the American Society of Hematology (ASH) has developed the following pediatric-to-adult transition toolkit. The toolkit provides both an assessment and summary form that are designed to facilitate conversations betweenpatients, parents
AMERICAN SOCIETY OF HEMATOLOGY The world's largest professional society serving both clinicians and scientists around the world who are working to conquer blood diseases. BLOOD HERISHANU COVID VACCINE AND CLL Blood (www.bloodjournal.org), the most cited peer-reviewed publication in the field of hematology, is available weekly in print and online. Blood is a journal of the American Society of Hematology (ASH) (www.hematology.org).. Contact: Leah Enser, American Society of Hematology lenser@hematology.org; 202-552-4927COVID-19 AND CML
At this time, based on best available information, patients with chronic myeloid leukemia (CML) are considered appropriate to receive vaccines against COVID-19. While rare special circumstances may exist, most patients, whether early in treatment, in ongoing response, in deep remission, or off therapy having pursued ‘treatment freeremission
ASH CLINICAL PRACTICE GUIDELINES ASH Clinical Practice Guidelines. ASH Guidelines are developed by leading clinical, methodological, and patient experts through a rigorous process to review evidence and write actionable recommendations. Our state-of-the-art methodology ensures that they meet the highest standards for trustworthiness and transparency. Guideline panels are HEMATOLOGY REVIEW SERIES The ASH Hematology Review Series is designed for fellows preparing to take the internal medicine hematology certification exam or those desiring a comprehensive update of hematology standards of care. This series provides a free review of hematology patterned after the American Board of Internal Medicine (ABIM) Certification ExaminationBlueprint.
COVID-19 AND CLL
Phone 202-776-0544 Toll Free 866-828-1231 Fax 202-776-0545 COVID-19 AND MULTIPLE MYELOMA Multiple myeloma patients with active disease need treatment to avoid morbidity and mortality, despite the COVID-19 pandemic; however, treatment can be individualized to limit additional exposure to COVID-19. For example, we recommend starting triplet therapy with bortezomib, lenalidomide and dexamethasone (RVD) for 6- 12 cyclesfollowed by
COVID-19 AND MYELODYSPLASTIC SYNDROMES There are no data indicating that patients with MDS are more likely to contract COVID-19 than patients with healthy bone marrows. Studies from Italy, the US, UK, and China indicate a higher mortality rate from COVID-19 among patients with a history of cancer, including hematological malignancy, compared to those without such a history.COVID-19 AND ITP
Severe COVID-19 infection is accompanied by a risk of thrombosis, but there is no evidence that this risk is increased by raising platelet counts to hemostatic levels or exacerbated by any specific form of ITP management, even splenectomy and thrombopoietic (TPO) agents which may be associated with some excess thrombosis in non-COVID ITP settings. COVID-19 AND MYELOPROLIFERATIVE NEOPLASMS The risks of bleeding on anticoagulation are higher in MPN patients, particularly in those with prior hemorrhages or extreme thrombocytosis or thrombocytopenia. The risk is even higher in MPN patients with hepatic failure (INR >1.5) or severe renal failure (filtration rate < 30ml/min per m2). We strongly recommend that COVID-19 infected and AMERICAN SOCIETY OF HEMATOLOGY The world's largest professional society serving both clinicians and scientists around the world who are working to conquer blood diseases. BLOOD HERISHANU COVID VACCINE AND CLL Blood (www.bloodjournal.org), the most cited peer-reviewed publication in the field of hematology, is available weekly in print and online. Blood is a journal of the American Society of Hematology (ASH) (www.hematology.org).. Contact: Leah Enser, American Society of Hematology lenser@hematology.org; 202-552-4927COVID-19 AND CML
At this time, based on best available information, patients with chronic myeloid leukemia (CML) are considered appropriate to receive vaccines against COVID-19. While rare special circumstances may exist, most patients, whether early in treatment, in ongoing response, in deep remission, or off therapy having pursued ‘treatment freeremission
ASH CLINICAL PRACTICE GUIDELINES ASH Clinical Practice Guidelines. ASH Guidelines are developed by leading clinical, methodological, and patient experts through a rigorous process to review evidence and write actionable recommendations. Our state-of-the-art methodology ensures that they meet the highest standards for trustworthiness and transparency. Guideline panels are HEMATOLOGY REVIEW SERIES The ASH Hematology Review Series is designed for fellows preparing to take the internal medicine hematology certification exam or those desiring a comprehensive update of hematology standards of care. This series provides a free review of hematology patterned after the American Board of Internal Medicine (ABIM) Certification ExaminationBlueprint.
COVID-19 AND CLL
Phone 202-776-0544 Toll Free 866-828-1231 Fax 202-776-0545 COVID-19 AND MULTIPLE MYELOMA Multiple myeloma patients with active disease need treatment to avoid morbidity and mortality, despite the COVID-19 pandemic; however, treatment can be individualized to limit additional exposure to COVID-19. For example, we recommend starting triplet therapy with bortezomib, lenalidomide and dexamethasone (RVD) for 6- 12 cyclesfollowed by
COVID-19 AND MYELODYSPLASTIC SYNDROMES There are no data indicating that patients with MDS are more likely to contract COVID-19 than patients with healthy bone marrows. Studies from Italy, the US, UK, and China indicate a higher mortality rate from COVID-19 among patients with a history of cancer, including hematological malignancy, compared to those without such a history.COVID-19 AND ITP
Severe COVID-19 infection is accompanied by a risk of thrombosis, but there is no evidence that this risk is increased by raising platelet counts to hemostatic levels or exacerbated by any specific form of ITP management, even splenectomy and thrombopoietic (TPO) agents which may be associated with some excess thrombosis in non-COVID ITP settings. COVID-19 AND MYELOPROLIFERATIVE NEOPLASMS The risks of bleeding on anticoagulation are higher in MPN patients, particularly in those with prior hemorrhages or extreme thrombocytosis or thrombocytopenia. The risk is even higher in MPN patients with hepatic failure (INR >1.5) or severe renal failure (filtration rate < 30ml/min per m2). We strongly recommend that COVID-19 infected andCOVID-19 RESOURCES
Rare cases of thrombosis with thrombocytopenia have been reported following vaccination with the Johnson & Johnson/Janssen COVID-19 vaccine. A recent one-hour seminar reviewed the background, diagnosis, and clinical management of this emerging disorder with experts from Centers for Disease Control (CDC) and the American Society ofHematology.
COVID-19 AND MYELODYSPLASTIC SYNDROMES There are no data indicating that patients with MDS are more likely to contract COVID-19 than patients with healthy bone marrows. Studies from Italy, the US, UK, and China indicate a higher mortality rate from COVID-19 among patients with a history of cancer, including hematological malignancy, compared to those without such a history. ASH CLINICAL PRACTICE GUIDELINES ASH Clinical Practice Guidelines. ASH Guidelines are developed by leading clinical, methodological, and patient experts through a rigorous process to review evidence and write actionable recommendations. Our state-of-the-art methodology ensures that they meet the highest standards for trustworthiness and transparency. Guideline panels areASH MEMBERSHIP
ASH Membership. Join a diverse community of more than 18,000 hematologists who are working to conquer blood diseases worldwide. Whether you are a medical student planning your career in hematology or an established physician or scientist with years of experience in the field, ASH offers benefits and opportunities for hematologistsaround the
COVID-19 AND INDOLENT LYMPHOMAS According to one report, the more intensive the therapy, the greater the impact on clinical outcomes from COVID-19. Furthermore, patients with lymphoma may have an increased susceptibility to infection with SARS-CoV-2. Patients should be encouraged to be vaccinated for the flu and cautioned to follow recommendations for reducing risks of COVID-19 AND COAGULOPATHY The most common pattern of coagulopathy observed in patients hospitalized with COVID-19 is characterized by elevations in fibrinogen and D-dimer levels, and mild prolongation of PT/aPTT. This correlates with a parallel rise in markers of inflammation (e.g. CRP). Unlike the pattern seen in classic DIC from bacterial sepsis or trauma COVID-19 AND D-DIMER Although it is not clear what effect anticoagulation has on D-dimer levels in the setting of COVID-19, very low D-dimer levels are usually observed in patients receiving anticoagulation. Because D-dimer is a product of cross-linked fibrin, it is considered a sensitive biomarker to rule out venous thromboembolism. LEGENDS IN HEMATOLOGY Legends in Hematology. Many hematologists have been instrumental in the development of ASH and have greatly advanced the field through their numerous contributions. Meet some of these notable leaders profiled as part of ASH's 50th anniversary in 2008 by following the links below to read their profiles and hear their insights about thefield and
HEMATOLOGY IN-SERVICE EXAM ASH’s Hematology In-Service Exam (ISE) is a low-stakes exam intended to be used as a medical knowledge competency assessment tool that can also provide training program feedback about the effectiveness of their curriculum. Hematology training programs in North America and around the world have been using the Hematology ISE since 2009.ASH JOB CENTER
View Job. Louisiana Hematology Oncology Opening 210302. Pinnacle Health Group, Slidell, LA | MAY 7, 2021. Hematology Oncology * Competitive salary starts at $450K (commensurate with experience and training) * CME reimbursement and paid time off, Sign on bonuses, Relocation assistance, Paid vacation and sick leave, Medical, dental AMERICAN SOCIETY OF HEMATOLOGY The world's largest professional society serving both clinicians and scientists around the world who are working to conquer blood diseases. BLOOD HERISHANU COVID VACCINE AND CLL Blood (www.bloodjournal.org), the most cited peer-reviewed publication in the field of hematology, is available weekly in print and online. Blood is a journal of the American Society of Hematology (ASH) (www.hematology.org).. Contact: Leah Enser, American Society of Hematology lenser@hematology.org; 202-552-4927COVID-19 AND CML
At this time, based on best available information, patients with chronic myeloid leukemia (CML) are considered appropriate to receive vaccines against COVID-19. While rare special circumstances may exist, most patients, whether early in treatment, in ongoing response, in deep remission, or off therapy having pursued ‘treatment freeremission
ASH CLINICAL PRACTICE GUIDELINES ASH Clinical Practice Guidelines. ASH Guidelines are developed by leading clinical, methodological, and patient experts through a rigorous process to review evidence and write actionable recommendations. Our state-of-the-art methodology ensures that they meet the highest standards for trustworthiness and transparency. Guideline panels are HEMATOLOGY REVIEW SERIES The ASH Hematology Review Series is designed for fellows preparing to take the internal medicine hematology certification exam or those desiring a comprehensive update of hematology standards of care. This series provides a free review of hematology patterned after the American Board of Internal Medicine (ABIM) Certification ExaminationBlueprint.
COVID-19 AND CLL
Phone 202-776-0544 Toll Free 866-828-1231 Fax 202-776-0545 COVID-19 AND MULTIPLE MYELOMA Multiple myeloma patients with active disease need treatment to avoid morbidity and mortality, despite the COVID-19 pandemic; however, treatment can be individualized to limit additional exposure to COVID-19. For example, we recommend starting triplet therapy with bortezomib, lenalidomide and dexamethasone (RVD) for 6- 12 cyclesfollowed by
COVID-19 AND MYELODYSPLASTIC SYNDROMES There are no data indicating that patients with MDS are more likely to contract COVID-19 than patients with healthy bone marrows. Studies from Italy, the US, UK, and China indicate a higher mortality rate from COVID-19 among patients with a history of cancer, including hematological malignancy, compared to those without such a history.COVID-19 AND ITP
Severe COVID-19 infection is accompanied by a risk of thrombosis, but there is no evidence that this risk is increased by raising platelet counts to hemostatic levels or exacerbated by any specific form of ITP management, even splenectomy and thrombopoietic (TPO) agents which may be associated with some excess thrombosis in non-COVID ITP settings. COVID-19 AND MYELOPROLIFERATIVE NEOPLASMS The risks of bleeding on anticoagulation are higher in MPN patients, particularly in those with prior hemorrhages or extreme thrombocytosis or thrombocytopenia. The risk is even higher in MPN patients with hepatic failure (INR >1.5) or severe renal failure (filtration rate < 30ml/min per m2). We strongly recommend that COVID-19 infected and AMERICAN SOCIETY OF HEMATOLOGY The world's largest professional society serving both clinicians and scientists around the world who are working to conquer blood diseases. BLOOD HERISHANU COVID VACCINE AND CLL Blood (www.bloodjournal.org), the most cited peer-reviewed publication in the field of hematology, is available weekly in print and online. Blood is a journal of the American Society of Hematology (ASH) (www.hematology.org).. Contact: Leah Enser, American Society of Hematology lenser@hematology.org; 202-552-4927COVID-19 AND CML
At this time, based on best available information, patients with chronic myeloid leukemia (CML) are considered appropriate to receive vaccines against COVID-19. While rare special circumstances may exist, most patients, whether early in treatment, in ongoing response, in deep remission, or off therapy having pursued ‘treatment freeremission
ASH CLINICAL PRACTICE GUIDELINES ASH Clinical Practice Guidelines. ASH Guidelines are developed by leading clinical, methodological, and patient experts through a rigorous process to review evidence and write actionable recommendations. Our state-of-the-art methodology ensures that they meet the highest standards for trustworthiness and transparency. Guideline panels are HEMATOLOGY REVIEW SERIES The ASH Hematology Review Series is designed for fellows preparing to take the internal medicine hematology certification exam or those desiring a comprehensive update of hematology standards of care. This series provides a free review of hematology patterned after the American Board of Internal Medicine (ABIM) Certification ExaminationBlueprint.
COVID-19 AND CLL
Phone 202-776-0544 Toll Free 866-828-1231 Fax 202-776-0545 COVID-19 AND MULTIPLE MYELOMA Multiple myeloma patients with active disease need treatment to avoid morbidity and mortality, despite the COVID-19 pandemic; however, treatment can be individualized to limit additional exposure to COVID-19. For example, we recommend starting triplet therapy with bortezomib, lenalidomide and dexamethasone (RVD) for 6- 12 cyclesfollowed by
COVID-19 AND MYELODYSPLASTIC SYNDROMES There are no data indicating that patients with MDS are more likely to contract COVID-19 than patients with healthy bone marrows. Studies from Italy, the US, UK, and China indicate a higher mortality rate from COVID-19 among patients with a history of cancer, including hematological malignancy, compared to those without such a history.COVID-19 AND ITP
Severe COVID-19 infection is accompanied by a risk of thrombosis, but there is no evidence that this risk is increased by raising platelet counts to hemostatic levels or exacerbated by any specific form of ITP management, even splenectomy and thrombopoietic (TPO) agents which may be associated with some excess thrombosis in non-COVID ITP settings. COVID-19 AND MYELOPROLIFERATIVE NEOPLASMS The risks of bleeding on anticoagulation are higher in MPN patients, particularly in those with prior hemorrhages or extreme thrombocytosis or thrombocytopenia. The risk is even higher in MPN patients with hepatic failure (INR >1.5) or severe renal failure (filtration rate < 30ml/min per m2). We strongly recommend that COVID-19 infected andCOVID-19 RESOURCES
Rare cases of thrombosis with thrombocytopenia have been reported following vaccination with the Johnson & Johnson/Janssen COVID-19 vaccine. A recent one-hour seminar reviewed the background, diagnosis, and clinical management of this emerging disorder with experts from Centers for Disease Control (CDC) and the American Society ofHematology.
COVID-19 AND MYELODYSPLASTIC SYNDROMES There are no data indicating that patients with MDS are more likely to contract COVID-19 than patients with healthy bone marrows. Studies from Italy, the US, UK, and China indicate a higher mortality rate from COVID-19 among patients with a history of cancer, including hematological malignancy, compared to those without such a history. ASH CLINICAL PRACTICE GUIDELINES ASH Clinical Practice Guidelines. ASH Guidelines are developed by leading clinical, methodological, and patient experts through a rigorous process to review evidence and write actionable recommendations. Our state-of-the-art methodology ensures that they meet the highest standards for trustworthiness and transparency. Guideline panels areASH MEMBERSHIP
ASH Membership. Join a diverse community of more than 18,000 hematologists who are working to conquer blood diseases worldwide. Whether you are a medical student planning your career in hematology or an established physician or scientist with years of experience in the field, ASH offers benefits and opportunities for hematologistsaround the
COVID-19 AND INDOLENT LYMPHOMAS According to one report, the more intensive the therapy, the greater the impact on clinical outcomes from COVID-19. Furthermore, patients with lymphoma may have an increased susceptibility to infection with SARS-CoV-2. Patients should be encouraged to be vaccinated for the flu and cautioned to follow recommendations for reducing risks of COVID-19 AND COAGULOPATHY The most common pattern of coagulopathy observed in patients hospitalized with COVID-19 is characterized by elevations in fibrinogen and D-dimer levels, and mild prolongation of PT/aPTT. This correlates with a parallel rise in markers of inflammation (e.g. CRP). Unlike the pattern seen in classic DIC from bacterial sepsis or trauma COVID-19 AND D-DIMER Although it is not clear what effect anticoagulation has on D-dimer levels in the setting of COVID-19, very low D-dimer levels are usually observed in patients receiving anticoagulation. Because D-dimer is a product of cross-linked fibrin, it is considered a sensitive biomarker to rule out venous thromboembolism. LEGENDS IN HEMATOLOGY Legends in Hematology. Many hematologists have been instrumental in the development of ASH and have greatly advanced the field through their numerous contributions. Meet some of these notable leaders profiled as part of ASH's 50th anniversary in 2008 by following the links below to read their profiles and hear their insights about thefield and
HEMATOLOGY IN-SERVICE EXAM ASH’s Hematology In-Service Exam (ISE) is a low-stakes exam intended to be used as a medical knowledge competency assessment tool that can also provide training program feedback about the effectiveness of their curriculum. Hematology training programs in North America and around the world have been using the Hematology ISE since 2009.ASH JOB CENTER
View Job. Louisiana Hematology Oncology Opening 210302. Pinnacle Health Group, Slidell, LA | MAY 7, 2021. Hematology Oncology * Competitive salary starts at $450K (commensurate with experience and training) * CME reimbursement and paid time off, Sign on bonuses, Relocation assistance, Paid vacation and sick leave, Medical, dental AMERICAN SOCIETY OF HEMATOLOGY The world's largest professional society serving both clinicians and scientists around the world who are working to conquer blood diseases. BLOOD HERISHANU COVID VACCINE AND CLL Blood (www.bloodjournal.org), the most cited peer-reviewed publication in the field of hematology, is available weekly in print and online. Blood is a journal of the American Society of Hematology (ASH) (www.hematology.org).. Contact: Leah Enser, American Society of Hematology lenser@hematology.org; 202-552-4927COVID-19 AND CML
At this time, based on best available information, patients with chronic myeloid leukemia (CML) are considered appropriate to receive vaccines against COVID-19. While rare special circumstances may exist, most patients, whether early in treatment, in ongoing response, in deep remission, or off therapy having pursued ‘treatment freeremission
ASH CLINICAL PRACTICE GUIDELINES ASH Clinical Practice Guidelines. ASH Guidelines are developed by leading clinical, methodological, and patient experts through a rigorous process to review evidence and write actionable recommendations. Our state-of-the-art methodology ensures that they meet the highest standards for trustworthiness and transparency. Guideline panels are HEMATOLOGY REVIEW SERIES The ASH Hematology Review Series is designed for fellows preparing to take the internal medicine hematology certification exam or those desiring a comprehensive update of hematology standards of care. This series provides a free review of hematology patterned after the American Board of Internal Medicine (ABIM) Certification ExaminationBlueprint.
COVID-19 AND CLL
Phone 202-776-0544 Toll Free 866-828-1231 Fax 202-776-0545 COVID-19 AND MULTIPLE MYELOMA Multiple myeloma patients with active disease need treatment to avoid morbidity and mortality, despite the COVID-19 pandemic; however, treatment can be individualized to limit additional exposure to COVID-19. For example, we recommend starting triplet therapy with bortezomib, lenalidomide and dexamethasone (RVD) for 6- 12 cyclesfollowed by
COVID-19 AND MYELODYSPLASTIC SYNDROMES There are no data indicating that patients with MDS are more likely to contract COVID-19 than patients with healthy bone marrows. Studies from Italy, the US, UK, and China indicate a higher mortality rate from COVID-19 among patients with a history of cancer, including hematological malignancy, compared to those without such a history.COVID-19 AND ITP
Severe COVID-19 infection is accompanied by a risk of thrombosis, but there is no evidence that this risk is increased by raising platelet counts to hemostatic levels or exacerbated by any specific form of ITP management, even splenectomy and thrombopoietic (TPO) agents which may be associated with some excess thrombosis in non-COVID ITP settings. COVID-19 AND MYELOPROLIFERATIVE NEOPLASMS The risks of bleeding on anticoagulation are higher in MPN patients, particularly in those with prior hemorrhages or extreme thrombocytosis or thrombocytopenia. The risk is even higher in MPN patients with hepatic failure (INR >1.5) or severe renal failure (filtration rate < 30ml/min per m2). We strongly recommend that COVID-19 infected and AMERICAN SOCIETY OF HEMATOLOGY The world's largest professional society serving both clinicians and scientists around the world who are working to conquer blood diseases. BLOOD HERISHANU COVID VACCINE AND CLL Blood (www.bloodjournal.org), the most cited peer-reviewed publication in the field of hematology, is available weekly in print and online. Blood is a journal of the American Society of Hematology (ASH) (www.hematology.org).. Contact: Leah Enser, American Society of Hematology lenser@hematology.org; 202-552-4927COVID-19 AND CML
At this time, based on best available information, patients with chronic myeloid leukemia (CML) are considered appropriate to receive vaccines against COVID-19. While rare special circumstances may exist, most patients, whether early in treatment, in ongoing response, in deep remission, or off therapy having pursued ‘treatment freeremission
ASH CLINICAL PRACTICE GUIDELINES ASH Clinical Practice Guidelines. ASH Guidelines are developed by leading clinical, methodological, and patient experts through a rigorous process to review evidence and write actionable recommendations. Our state-of-the-art methodology ensures that they meet the highest standards for trustworthiness and transparency. Guideline panels are HEMATOLOGY REVIEW SERIES The ASH Hematology Review Series is designed for fellows preparing to take the internal medicine hematology certification exam or those desiring a comprehensive update of hematology standards of care. This series provides a free review of hematology patterned after the American Board of Internal Medicine (ABIM) Certification ExaminationBlueprint.
COVID-19 AND CLL
Phone 202-776-0544 Toll Free 866-828-1231 Fax 202-776-0545 COVID-19 AND MULTIPLE MYELOMA Multiple myeloma patients with active disease need treatment to avoid morbidity and mortality, despite the COVID-19 pandemic; however, treatment can be individualized to limit additional exposure to COVID-19. For example, we recommend starting triplet therapy with bortezomib, lenalidomide and dexamethasone (RVD) for 6- 12 cyclesfollowed by
COVID-19 AND MYELODYSPLASTIC SYNDROMES There are no data indicating that patients with MDS are more likely to contract COVID-19 than patients with healthy bone marrows. Studies from Italy, the US, UK, and China indicate a higher mortality rate from COVID-19 among patients with a history of cancer, including hematological malignancy, compared to those without such a history.COVID-19 AND ITP
Severe COVID-19 infection is accompanied by a risk of thrombosis, but there is no evidence that this risk is increased by raising platelet counts to hemostatic levels or exacerbated by any specific form of ITP management, even splenectomy and thrombopoietic (TPO) agents which may be associated with some excess thrombosis in non-COVID ITP settings. COVID-19 AND MYELOPROLIFERATIVE NEOPLASMS The risks of bleeding on anticoagulation are higher in MPN patients, particularly in those with prior hemorrhages or extreme thrombocytosis or thrombocytopenia. The risk is even higher in MPN patients with hepatic failure (INR >1.5) or severe renal failure (filtration rate < 30ml/min per m2). We strongly recommend that COVID-19 infected andCOVID-19 RESOURCES
Rare cases of thrombosis with thrombocytopenia have been reported following vaccination with the Johnson & Johnson/Janssen COVID-19 vaccine. A recent one-hour seminar reviewed the background, diagnosis, and clinical management of this emerging disorder with experts from Centers for Disease Control (CDC) and the American Society ofHematology.
COVID-19 AND MYELODYSPLASTIC SYNDROMES There are no data indicating that patients with MDS are more likely to contract COVID-19 than patients with healthy bone marrows. Studies from Italy, the US, UK, and China indicate a higher mortality rate from COVID-19 among patients with a history of cancer, including hematological malignancy, compared to those without such a history. ASH CLINICAL PRACTICE GUIDELINES ASH Clinical Practice Guidelines. ASH Guidelines are developed by leading clinical, methodological, and patient experts through a rigorous process to review evidence and write actionable recommendations. Our state-of-the-art methodology ensures that they meet the highest standards for trustworthiness and transparency. Guideline panels areASH MEMBERSHIP
ASH Membership. Join a diverse community of more than 18,000 hematologists who are working to conquer blood diseases worldwide. Whether you are a medical student planning your career in hematology or an established physician or scientist with years of experience in the field, ASH offers benefits and opportunities for hematologistsaround the
COVID-19 AND INDOLENT LYMPHOMAS According to one report, the more intensive the therapy, the greater the impact on clinical outcomes from COVID-19. Furthermore, patients with lymphoma may have an increased susceptibility to infection with SARS-CoV-2. Patients should be encouraged to be vaccinated for the flu and cautioned to follow recommendations for reducing risks of COVID-19 AND COAGULOPATHY The most common pattern of coagulopathy observed in patients hospitalized with COVID-19 is characterized by elevations in fibrinogen and D-dimer levels, and mild prolongation of PT/aPTT. This correlates with a parallel rise in markers of inflammation (e.g. CRP). Unlike the pattern seen in classic DIC from bacterial sepsis or trauma COVID-19 AND D-DIMER Although it is not clear what effect anticoagulation has on D-dimer levels in the setting of COVID-19, very low D-dimer levels are usually observed in patients receiving anticoagulation. Because D-dimer is a product of cross-linked fibrin, it is considered a sensitive biomarker to rule out venous thromboembolism. LEGENDS IN HEMATOLOGY Legends in Hematology. Many hematologists have been instrumental in the development of ASH and have greatly advanced the field through their numerous contributions. Meet some of these notable leaders profiled as part of ASH's 50th anniversary in 2008 by following the links below to read their profiles and hear their insights about thefield and
HEMATOLOGY IN-SERVICE EXAM ASH’s Hematology In-Service Exam (ISE) is a low-stakes exam intended to be used as a medical knowledge competency assessment tool that can also provide training program feedback about the effectiveness of their curriculum. Hematology training programs in North America and around the world have been using the Hematology ISE since 2009.ASH JOB CENTER
View Job. Louisiana Hematology Oncology Opening 210302. Pinnacle Health Group, Slidell, LA | MAY 7, 2021. Hematology Oncology * Competitive salary starts at $450K (commensurate with experience and training) * CME reimbursement and paid time off, Sign on bonuses, Relocation assistance, Paid vacation and sick leave, Medical, dental Jump to Main Content* About ASH
* ASH Foundation
*
__ Log in or create an account*
Submit __ __
*
* Research
* Education
* Advocacy
* Careers
* Meetings
* Publications
* Awards
* Newsroom
* About ASH
* ASH Foundation
* My Account
* Membership
* Global Initiatives* ASH Store
Helping hematologists conquer blood diseases worldwide* Research
* Education
* Advocacy
* Careers
* Meetings
* Publications
* Awards
* Newsroom
REVISIT CONTENT FROM THE 62ND ASH ANNUAL MEETING Recorded sessions from the all-virtual 2020 ASH Annual Meeting are nowavailable.
LEARN MORE
LANDING PAGE
__
ASH'S COMMITMENT TO DIVERSITY, EQUITY, AND INCLUSION IN HEALTH CARELearn more
LATEST UPDATES
ASH COVID-19 RESOURCES ASH RC COVID 19 REGISTRY FOR HEMATOLOGY This global public reference tool is part of the ASH RC Data Hubplatform.
Learn more
CLINICAL TRIAL SUPPORT CENTER The Leukemia & Lymphoma Society's CTSC can help physicians provide their patients with assistance finding and enrolling in clinicaltrials.
Learn More
MEETINGS
2021 ASH ANNUAL MEETING AND EXPOSITION December 11-14, 2021 Learnmore
-------------------------RESEARCH
The American Society of Hematology (ASH) leads the world in promoting and supporting clinical and scientific hematology research through its many innovative award programs, meetings, publications, and advocacyefforts.
ASH Research Programs and Awards Learn More ASH Agenda for Hematology Research Learn More Annual Meeting Abstracts Learn More View More ASH Research -------------------------EDUCATION
__ Guidelines & Quality Care __ Professional Development __ Educational Programs The American Society of Hematology offers a wide array of educational products and services for clinicians and scientists at any stage intheir careers.
FOR CLINICIANS
ASH is committed to helping practicing hematologists provide quality care to patients, continue their professional development, and enhance their knowledge and expertise. Learn More >FOR TRAINEES
Whether you are medical student, resident, or fellow, ASH provides many programs and resources to help you advance your career as a hematologist. Learn More >FOR EDUCATORS
As the world's leading provider of hematology education, ASH offers many programs and resources for educators working in the field of hematology. Learn More >FOR PATIENTS
ASH has developed the resources to educate about the importance of healthy blood and to raise the awareness of common blood diseases.Learn More >
View More ASH Education -------------------------PUBLICATIONS
ASH publications include both clinical and scientific research, and education in the field of hematology. With an impact factor of 16.601 (2018), _Blood_ is the most cited peer-reviewed publication in the field of hematology. It provides an international forum for the publication of original articles describing basic laboratory, translational, and clinical investigations in hematology. _Blood Advances_ is a semimonthly medical journal published by the American Society of Hematology. It is the first journal to join the _Blood_ family in 70 years and is a peer-reviewed, online only, open access journal. Under the direction of founding editor-in-chief Robert Negrin, MD, Stanford University Medical Center, Stanford, CA, the inaugural issue debuted on November 29, 2016. _The Hematologist: ASH News and Reports_, the American Society of Hematology’s member newsletter, is designed for the broad constituency of ASH, ranging from basic scientists to practicing clinicians, all working toward the ultimate goal of conquering blooddiseases.
_ASH Clinical News_, a monthly news magazine specifically designed to appeal to clinical practitioners in hematology and oncology, provides timely updates in the field by reporting on key medical meetings, clinical trials, innovative technology, and influential papers in theliterature.
View All Publications -------------------------GET INVOLVED
ASH is always looking for ways to better serve all communities of clinicians and scientists working to conquer blood disease worldwide. Whether you are looking to take action by being an advocate for hematology, support the foundation through donation, or joining a diverse community of more than 17,000 hematologists, you will help conquer blood diseases worldwide.ADVOCACY
ASH is the leader in representing the interests of scientists and clinicians working in the field of hematology on Capitol Hill and within federal agencies concerned with the study and treatment of blood-related diseases. Learn MoreDONATE
Donations to the COVID 19 Fund will support ASH projects addressing the COVID pandemic. These include the ASH Research Collaborative’s COVID-19 Registry for Hematology, currently capturing data on people who test positive for COVID-19 and have been or are currently being treated for benign and malignant hematologic disorders. Learn MoreMEMBERSHIP
Whether you are a medical student planning your career in hematology or an established physician or scientist with years of experience in the field, ASH offers benefits and opportunities for hematologists around the globe at every career level. Learn More Learn About ASH Global Initiatives -------------------------ASH FAMILY OF SITES
ASH Publications
ASH Store
ASH Pocket Guides
ASH Job Center
ASH On Demand
ASH Image Bank
ASH Academy
ASH provides the most current practice tools, clinical support, and educational products in hematology that you need for every stage of your career. Our family of sites, developed by subject-matter experts, are designed to help physicians improve their medical knowledge, engage in quality activities, meet and learn from thousands of hematologists worldwide and continue to help conquer blood diseasesworldwide.
Learn More about ASH American Society of Hematology 2021 L Street NW, Suite 900, Washington, DC 20036Contact
Phone 202-776-0544
Toll Free 866-828-1231Fax 202-776-0545
Social
__ __
__
__
Copyright © 2021 by American Society of Hematology Support Opportunities |Privacy Policy |Terms of Service|Contact Us
LAST REVISED: MAY 1, 2018 Thank you for your interest in how ASH uses cookies on our Sites. We have provided this Cookie Policy to provide you with transparency so you can make informed choices about how your personal data in the form of your internet protocol address is tracked utilizing cookies by ASH and other third parties. This Cookie Policy explains how your personal data is shared and analyzed by our third-party vendor service providers to improve the performance and user satisfaction of our Sites, to help those Sites function properly for your use and convenience, to enable third-party advertisers to serve you ads, to provide you with other content that is optimized for you based upon your use of the Sites, and your ability to share such content on social media. Identification of Individuals to Contact at ASH regarding questions concerning Cookies We hope that this Cookie Policy helps you understand and provides a good explanation for our use of cookies on the Sites. If after reviewing this policy you have any further questions for us, require assistance or have requests based upon the information provide here, please contact us at customerservice@hematology.org. What are Cookies? Cookies are small physical data files that are automatically placed on to your computer’s browser as you navigate the web. Cookies can provide a great deal of insight into your activity and preferences, and in some cases can be used to identify you. For this reason we want to provide as much information to you about the cookies we use and how we manage cookies when you provide us with your consent. Your consent enables us to use cookies to track your activity across our Sites in order to accomplish the objectives outlined in this Cookie Policy. Visiting our Sites This Cookie Policy shall apply to the ASH domain owned by us any subsite, subdomain, subdirectory, virtual site, or virtual directory thereof (each, a “Site” and collectively the "Sites") For some of our Sites, we may post a Cookie Policy that is Site specific. We do this in order to best describe the use of cookies for Sites that are administered by our third party vendor partners. By posting a separate and site specific policy on these selected Sites, we are able to provide transparency to you and describe in detail where the use of cookies is configured in a way that is different than how ASH typically manages cookies on its Sites or as explained in this Cookie Policy. The reasons for this is that some of our third party site administrators are in the process of developing and upgrading their compliance and technical use capabilities in the interest of providing maximum choice to visitors to the Sites. These Sites include www.bloodjournal.org, www.bloodadvances.org, www.ash-sap.org and www.asheducationbook.hematology.org. For these Sites, we will continue to update you as the technical and compliance capabilities are enhanced and additional choices regarding the use of cookies becomes available to you. Obtaining Your Consent and Your Choices The first time you visit the Sites, you will be provided with a Cookie Disclosure “pop up” window that informs you “ASH uses cookies to personalize content and ads in order to provide social media features and to analyze our traffic. We also share information about your use of our site with our social media, advertising and analytics partners who may combine with other information that you’ve provided to them or that they have collected from your use of their services.” ASH will require you to identify by checking the boxes designed to determine your specific choices regarding the categories of Cookies to be used each time you visit the Sites. By clicking on the “OK” button, you are providing ASH with your consent to utilize the relevant cookies for each of the individual categories chosen by you which are described more fully below in this Cookie Policy. Changing Your Choices Note that each time you return to the site, you have the option of changing your choices by clicking on the Cookie Settings tab and revising your choices if you so desire. If you revise your choices, ASH will clear the cookies in the specific categories you have selected and those cookies will no longer track your activity on the Sites. If you do not ask for your settings to be changed, your previous choices and the previous consent you provided to ASH will apply to your current session on the Sites. Description of the General Categories of Cookies for Selection and Opt In: Necessary: These cookies are essential to the functionality of the Sites in order to facilitate your use of the Sites and its features and in order to enable you to move around the Sites smoothly. Without these cookies, we may not be able to provide certain services or features, and the Sites will not properly function. Unfortunately, these cookies cannot be disabled or modified, which is why we refer to these as necessary. Preferences: In some circumstances, we may use functionality cookies which we describe as “Preferences” cookies. The cookies allow us to remember the choices you make while browsing the Sites, and to provide enhanced and more personalized content and features, such as customizing a certain webpage, remembering if we have asked you to participate in a promotion and for other services you request, like watching a video or commenting on a blog. In order to permit your connection to the Sites, our servers receive and record information about your computer, device, and browser, including your IP address, browser type, and other software or hardware information. If you access the Sites from a mobile or other device, we may collect a unique device identifier assigned to that device ("UDID"), geolocation data, or other transactional information for that device. All of these features help us to improve your visit to the Site. Statistics and Analytics: We and our third-party vendor service providers may use analytics cookies, which are sometimes called performance or analytics cookies, to collect information about your use of the Sites and enable us to improve the way it works and prepare statistical analysis of such analytics. Analytics cookies collect information about how you use the Sites, for instance, which pages you go to most. The information allows us to see the overall patterns of usage on the Sites, help us record any difficulties you have with the Sites, and show us whether our advertising is effective or not. Marketing: We and our third-party vendor partners may use advertising cookies to deliver ads that we believe are more relevant to you and your interests on our Sites and other sites. For example, we may use targeting or advertising cookies to customize the advertising and content you receive on our Sites, to limit the number of times you see the same ad on our Sites, and to help measure the effectiveness of our advertising campaigns. These cookies remember what you have looked at on the Sites and other sites, and may be combined with other information acquired from third parties, and we may share this information with other organizations, such as advertisers, in order the best determine how to drive content to you that you may find useful based upon your browsing experience. Within the category of marketing, we also include social plug-in tracking cookies that can be used to track both members and non-members of social networks for "additional" purposes such as behavioral advertising, analytics, and market research. For more information about targeting and advertising cookies and how you can opt out, visit: Network Advertising Initiative: http://www.networkadvertising.org/choices/ Digital Advertising Alliance: http://www.aboutads.info/choices/ http://www.allaboutcookies.org/manage-cookies/index.html How Do Third Parties Use Cookies on Our Sites in Connection With Our Services? In some circumstances, we may work with third parties to provide services on our Sites. For example, we use analytics services supported by third-party companies who generate analytics cookies on our behalf. We may not have access to these or remove third-party cookies, although we may use statistical information arising from the cookies provided by these third parties to customize content and for the other purposes described above. These companies may also transfer this information to other parties where required to do so by law, or where such other parties process the information on their behalf. Third-party advertisers and other organizations may also use their own cookies to collect information about your activities on our Site and/or the advertisements you have clicked on. This information, which may be combined with other information acquired from third parties, may be used by them to serve advertisements on our Sites and third party sites that they believe are most likely to be of interest to you based on content you have viewed. Third-party advertisers may also use this information to measure the effectiveness of their advertisements and to track aggregate usage statistics. We may not control these third-party cookies and their use may be governed by the privacy policies of the third parties employing these cookies. How Does My Opting Out of or Not Consenting to Cookies Work If There Are Third-Party Cookies You Cannot Access or Control? The cookie is a physical data file script that is set into the browser which captures the data in accordance with the instructions coded into the script which is set by the third parties. When you make your choices regarding our use of cookies, our third-party software service provider, CookieBot, ensures the specific scripts associated with these third party cookies are removed so that scripts corresponding to those cookies and providing instructions regarding data capture are disabled. Although the cookie is not specifically removed unless you clear your browser or take other action to block these cookies as described below, the tracking functionality is stopped by CookieBot’s software. How Can You Further Control Cookies on the Sites? You may outright refuse to accept cookies from the Sites at any time by activating the setting on your browser which allows you to refuse cookies. Further information about the procedure to follow in order to disable cookies can be found on your Internet browser provider’s website via your help screen. You may wish to refer to http://www.allaboutcookies.org/manage-cookies/index.html for information on commonly used browsers. Please note that by disabling or blocking any or all cookies, some features of the Sites may not operate as intended, or you may not have access to features or personalization available through the Site. Analytics cookies can also be managed via the following link: Google Analytics: http://tools.google.com/dlpage/gaoptout. How does ASH respond to Do Not Track signals? ASH utilizes a third-party software service provider, CookieBot, to manage consents for cookies utilized by the Sites. If you have enabled the your web browser’s DO NOT TRACK (DNT) settings Cookiebot will not set the third party cookie CookieConsentBulkTicket used for bulk consent. Changes and Revisions to This Cookie Policy Please take a look at the Last Revised date at the top of this page to see when this Cookie Policy was last revised. Any changes in this Cookie Policy will become effective when we make the revised Cookie Policy available on or through the Site. How Do Third Parties Use Cookies on Our Sites in Connection With Our Services? In some circumstances, we may work with third parties to provide services on our Sites. For example, we use analytics services supported by third-party companies who generate analytics cookies on our behalf. We may not have access to these or remove third-party cookies, although we may use statistical information arising from the cookies provided by these third parties to customize content and for the other purposes described above. These companies may also transfer this information to other parties where required to do so by law, or where such other parties process the information on their behalf. Third-party advertisers and other organizations may also use their own cookies to collect information about your activities on our Site and/or the advertisements you have clicked on. This information, which may be combined with other information acquired from third parties, may be used by them to serve advertisements on our Sites and third party sites that they believe are most likely to be of interest to you based on content you have viewed. Third-party advertisers may also use this information to measure the effectiveness of their advertisements and to track aggregate usage statistics. We may not control these third-party cookies and their use may be governed by the privacy policies of the third parties employing these cookies. How Does My Opting Out of or Not Consenting to Cookies Work If There Are Third-Party Cookies You Cannot Access or Control? The cookie is a physical data file script that is set into the browser which captures the data in accordance with the instructions coded into the script which is set by the third parties. When you make your choices regarding our use of cookies, our third-party software service provider, CookieBot, ensures the specific scripts associated with these third party cookies are removed so that scripts corresponding to those cookies and providing instructions regarding data capture are disabled. Although the cookie is not specifically removed unless you clear your browser or take other action to block these cookies as described below, the tracking functionality is stopped by CookieBot’s software. How Can You Further Control Cookies on the Sites? You may outright refuse to accept cookies from the Sites at any time by activating the setting on your browser which allows you to refuse cookies. Further information about the procedure to follow in order to disable cookies can be found on your Internet browser provider’s website via your help screen. You may wish to refer to http://www.allaboutcookies.org/manage-cookies/index.html for information on commonly used browsers. Please note that by disabling or blocking any or all cookies, some features of the Sites may not operate as intended, or you may not have access to features or personalization available through the Site. Analytics cookies can also be managed via the following link: Google Analytics: http://tools.google.com/dlpage/gaoptout. How does ASH respond to Do Not Track signals? ASH utilizes a third-party software service provider, CookieBot, to manage consents for cookies utilized by the Sites. If you have enabled the your web browser’s DO NOT TRACK (DNT) settings Cookiebot will not set the third party cookie CookieConsentBulkTicket used for bulk consent. Changes and Revisions to This Cookie Policy Please take a look at the Last Revised date at the top of this page to see when this Cookie Policy was last revised. Any changes in this Cookie Policy will become effective when we make the revised Cookie Policy available on or through the Site. Your consent applies to the following domains: ashrc2-hematology.cs59.force.com, www.ashresearchcollaborative.org, hematology.force.com, ashreasearchcollaborative.org, www.hematology.org, hematology.org, testing.hematology.org, eus-prd-1045176-xp3-cd.azurewebsites.net Your current state: Use necessary cookies only. Your current state: Do Not Sell My Personal Information. Your current state: Allow selection (Necessary, Preferences, Statistics, Marketing). Your current state: Allow all cookies. Your consent ID: Consent date: Change your consent | Withdraw your consent Do Not Sell My Personal Information Cookie declaration last updated on 5/5/21 by Cookiebot:
Necessary (24)
Necessary: These cookies are essential to the functionality of the Sites in order to facilitate your use of the Sites and its features and in order to enable you to move around the Sites smoothly. Without these cookies, we may not be able to provide certain services or features, and the Sites will not properly function. Unfortunately, these cookies cannot be disabled or modified, which is why we refer tothese as necessary.
NAME
PROVIDER
PURPOSE
EXPIRY
TYPE
__cfduid
Cludo
Used by the content network, Cloudflare, to identify trusted webtraffic.
30 days
HTTP Cookie
ARRAffinity
American Society of HematologyMicrosoft
Used to distribute traffic to the website on several servers in order to optimise response times.Session
HTTP Cookie
ARRAffinitySameSite
American Society of HematologyMicrosoft
Used to distribute traffic to the website on several servers in order to optimise response times.Session
HTTP Cookie
ASP.NET_SessionId
American Society of HematologyMicrosoft
Preserves the visitor's session state across page requests.Session
HTTP Cookie
CONSENT
YouTube
Used to detect if the visitor has accepted the marketing category in the cookie banner. This cookie is necessary for GDPR-compliance ofthe website.
6070 days
HTTP Cookie
CookieConsent
Cookiebot
Stores the user's cookie consent state for the current domain1 year
HTTP Cookie
CookieConsentPolicy
www.ashresearchcollaborative.org Stores the user's cookie consent state for the current domain1 year
HTTP Cookie
cookieSettingVerified www.ashresearchcollaborative.org Determines whether the visitor has accepted the cookie consent box. This ensures that the cookie consent box will not be presented againupon re-entry.
Session
HTTP Cookie
JSESSIONID
New Relic
American Society of Hematology Preserves users states across page requests.Session
HTTP Cookie
renderCtx
www.ashresearchcollaborative.org Necessary to facilitate client-side-rendering, which allows the website to place website scripts in the client’s browser.Session
HTTP Cookie
SESS#
Salesforce
Preserves users states across page requests.Session
HTTP Cookie
sfdc-stream
www.ashresearchcollaborative.org Used to maintain the overall functionality of the website: Assigns the user to a server and detects potential errors on specific servers, allowing the website to reassign the users to another server.1 day
HTTP Cookie
XSRF-TOKEN
Phone2 Action
Ensures visitor browsing-security by preventing cross-site request forgery. This cookie is essential for the security of the website andvisitor.
1 day
HTTP Cookie
Preferences (11)
Preferences: In some circumstances, we may use functionality cookies which we describe as “Preferences” cookies. The cookies allow us to remember the choices you make while browsing the Sites, and to provide enhanced and more personalized content and features, such as customizing a certain webpage, remembering if we have asked you to participate in a promotion and for other services you request, like watching a video or commenting on a blog. In order to permit your connection to the Sites, our servers receive and record information about your computer, device, and browser, including your IP address, browser type, and other software or hardware information. If you access the Sites from a mobile or other device, we may collect a unique device identifier assigned to that device ("UDID"), geolocation data, or other transactional information for that device. All of these features help us to improve your visit to the Site.NAME
PROVIDER
PURPOSE
EXPIRY
TYPE
addevent_track_cookieaddthisevent.com
If consent is given by the visitor, this cookie allows the website to add events into the visitor's calendar.1 year
HTTP Cookie
com.adobe.reactor.dataElementCookiesMigratedFlickr
Used in context with the cache-function on the website, facilitating data transfer between Adobe DTM onto Adobe Launch.Persistent
HTML Local Storage
com.adobe.reactor.dataElements.User ClassFlickr
Registers whether the user is logged in. This allows the website owner to make parts of the website inaccessible, based on the user'slog-in status.
Persistent
HTML Local Storage
com.adobe.reactor.dataElements.User IDFlickr
Registers statistical data on users' behaviour on the website. Used for internal analytics by the website operator.Persistent
HTML Local Storage
com.adobe.reactor.dataElements.User IntlFlickr
Determines the preferred language of the visitor. Allows the website to set the preferred language upon the visitor's re-entry.Persistent
HTML Local Storage
com.adobe.reactor.dataElements.User LanguageFlickr
Determines the preferred language of the visitor. Allows the website to set the preferred language upon the visitor's re-entry.Persistent
HTML Local Storage
CookieConsentBulkSetting-#Cookiebot
Enables cookie consent across multiple websitesPersistent
HTML Local Storage
hematology#lang
American Society of HematologyMicrosoft
Pending
Session
HTTP Cookie
tableau_locale
American Society of Hematology The cookie determines the preferred language and country-setting of the visitor - This allows the website to show content most relevant to that region and language.Session
HTTP Cookie
Statistics (28)
Statistics and Analytics: We and our third-party vendor service providers may use statistics cookies, which are sometimes called performance or analytics cookies, to collect information about your use of the Sites and enable us to improve the way it works and prepare statistical analysis of such analytics. Analytics cookies collect information about how you use the Sites, for instance, which pages you go to most. The information allows us to see the overall patterns of usage on the Sites, help us record any difficulties you have with the Sites, and show us whether our advertising is effective or not.NAME
PROVIDER
PURPOSE
EXPIRY
TYPE
_at.hist.#
Google Tag Manager
Used by the social sharing platform AddThis to store the user's usage history of the AddThis sharing widgetPersistent
HTML Local Storage
_ga
2 years
HTTP Cookie
_gat
1 day
HTTP Cookie
_gid
1 day
HTTP Cookie
ADRUM_BT1
American Society of Hematology This cookie is used to detect errors on the website - this information is sent to the website's support staff in order to optimize the visitor's experience on the website.1 day
HTTP Cookie
ADRUM_BTa
American Society of Hematology This cookie is used to detect errors on the website - this information is sent to the website's support staff in order to optimize the visitor's experience on the website.1 day
HTTP Cookie
BrowserId
Salesforce
Registers a unique ID that identifies the user's device for returnvisits.
1 year
HTTP Cookie
ce_clock
American Society of HematologyMicrosoft
Sets a timestamp for when the visitor entered the website. This is used for analytical purposes on the website.Persistent
HTML Local Storage
collect
channels.
Session
Pixel Tracker
jserrors/1/#
New Relic
Pending
Session
Pixel Tracker
ki_r
Qualaroo
Used to remember what questions the user has seen. This ensures that the same questions are not displayed to the user again.5 years
HTTP Cookie
ki_t
Qualaroo
Used to remember what questions the user has seen. This ensures that the same questions are not displayed to the user again.5 years
HTTP Cookie
personalization_id
2 years
HTTP Cookie
SC_ANALYTICS_GLOBAL_COOKIE American Society of HematologyMicrosoft
Used by Sitecore Engagement Analytics to identify the visitor on repeat visits to the website.10 years
HTTP Cookie
t
American Society of Hematology Stores data on which websites the user has visited.Session
HTTP Cookie
vuid
Vimeo
Collects data on the user's visits to the website, such as which pages have been read.2 years
HTTP Cookie
Marketing (39)
Marketing: We and our third-party vendor partners may use advertising cookies to deliver ads that we believe are more relevant to you and your interests on our Sites and other sites. For example, we may use targeting or advertising cookies to customize the advertising and content you receive on our Sites, to limit the number of times you see the same ad on our Sites, and to help measure the effectiveness of our advertising campaigns. These cookies remember what you have looked at on the Sites and other sites, and may be combined with other information acquired from third parties, and we may share this information with other organizations, such as advertisers, in order the best determine how to drive content to you that you may find useful based upon your browsing experience. Within the category of marketing, we also include social plug-in tracking cookies that can be used to track both members and non-members of social networks for "additional" purposes such as behavioral advertising, analytics, and market research. For more information about targeting and advertising cookies and how you can opt out, visit: Network Advertising Initiative: http://www.networkadvertising.org/choices/ Digital Advertising Alliance: http://www.aboutads.info/choices/ http://www.allaboutcookies.org/manage-cookies/index.htmlNAME
PROVIDER
PURPOSE
EXPIRY
TYPE
__atuvc
AddThis
Updates the counter of a website's social sharing features.13 months
HTTP Cookie
__atuvs
AddThis
Ensures that the updated counter is displayed to the user if a page is shared with the social sharing service, AddThis.1 day
HTTP Cookie
_at.cww
Google Tag Manager
Used by the social sharing platform AddThisPersistent
HTML Local Storage
_fbp
3 months
HTTP Cookie
ads/ga-audiences
websites.
Session
Pixel Tracker
at-lojson-cache-#
v1.addthisedge.com
Used by the social sharing platform AddThisPersistent
HTML Local Storage
at-rand
AddThis
Used by the social sharing platform AddThisPersistent
HTML Local Storage
BrowserId_sec
Salesforce
Collects data on user behaviour and interaction in order to optimize the website and make advertisement on the website morerelevant.
1 year
HTTP Cookie
ComponentDefStorage__MUTEX_X www.ashresearchcollaborative.org Used to track visitors on multiple websites, in order to present relevant advertisement based on the visitor's preferences.Persistent
HTML Local Storage
DT
American Society of Hematology Enables the visitor to share content from the website onto social media platforms or websites.2 years
HTTP Cookie
fr
3 months
HTTP Cookie
GlobalValueProviders__MUTEX_X www.ashresearchcollaborative.org Used to track visitors on multiple websites, in order to present relevant advertisement based on the visitor's preferences.Persistent
HTML Local Storage
i/adsct
content.
Session
Pixel Tracker
IDE
1 year
HTTP Cookie
loc
AddThis
Geolocation, which is used to help providers determine how users who share information with each other are geographically located(state level).
13 months
HTTP Cookie
pctrk
www.ashresearchcollaborative.org Tracks the individual sessions on the website, allowing the website to compile statistical data from multiple visits. This data can also be used to create leads for marketing purposes.1 year
HTTP Cookie
test_cookie
1 day
HTTP Cookie
tr
Session
Pixel Tracker
uvc
AddThis
Detects how often the social sharing service, AddThis, encountersthe same user.
13 months
HTTP Cookie
VISITOR_INFO1_LIVE
YouTube
Tries to estimate the users' bandwidth on pages with integratedYouTube videos.
179 days
HTTP Cookie
WIDGET::local::assignmentsSoundcloud
Used by audio-platform SoundCloud to implement, measure and improve their embedded content/service on the website - The collection of data also includes visitors’ interaction with embedded content/service. This can be used for statistics or marketing purposes.Persistent
HTML Local Storage
xtc
AddThis
Registers the user's sharing of content via social media.13 months
HTTP Cookie
YSC
YouTube
Registers a unique ID to keep statistics of what videos from YouTube the user has seen.Session
HTTP Cookie
yt.innertube::nextIdYouTube
Registers a unique ID to keep statistics of what videos from YouTube the user has seen.Persistent
HTML Local Storage
yt.innertube::requestsYouTube
Registers a unique ID to keep statistics of what videos from YouTube the user has seen.Persistent
HTML Local Storage
yt-remote-cast-availableYouTube
Pending
Session
HTML Local Storage
yt-remote-cast-installedYouTube
Stores the user's video player preferences using embedded YouTubevideo
Session
HTML Local Storage
yt-remote-connected-devicesYouTube
Stores the user's video player preferences using embedded YouTubevideo
Persistent
HTML Local Storage
yt-remote-device-id
YouTube
Stores the user's video player preferences using embedded YouTubevideo
Persistent
HTML Local Storage
yt-remote-fast-check-periodYouTube
Stores the user's video player preferences using embedded YouTubevideo
Session
HTML Local Storage
yt-remote-session-appYouTube
Stores the user's video player preferences using embedded YouTubevideo
Session
HTML Local Storage
yt-remote-session-nameYouTube
Stores the user's video player preferences using embedded YouTubevideo
Session
HTML Local Storage
Unclassified (28)
Unclassified cookies are cookies that we are in the process of classifying, together with the providers of individual cookies.NAME
PROVIDER
PURPOSE
EXPIRY
TYPE
Acceptance
American Society of HematologyPending
1 year
HTTP Cookie
CAMPAIGNS/forms
Phone2 Action
Pending
Persistent
HTML Local Storage
CAMPAIGNS/legislatorsPhone2 Action
Pending
Persistent
HTML Local Storage
CAMPAIGNS/navigationPhone2 Action
Pending
Persistent
HTML Local Storage
ce_cookie_check
Crazyegg
Pending
Session
HTTP Cookie
ce_get_top_level_domainCrazyegg
Pending
Session
HTTP Cookie
ce_need_secure_cookieCrazyegg
Pending
Session
HTTP Cookie
ComponentDefStorage__MUTEX_Y www.ashresearchcollaborative.orgPending
Persistent
HTML Local Storage
events/1/e19339791b
New Relic
Pending
Session
Pixel Tracker
force-proxy-stream
www.ashresearchcollaborative.orgPending
1 day
HTTP Cookie
force-stream
www.ashresearchcollaborative.orgPending
1 day
HTTP Cookie
GlobalValueProviders__MUTEX_Y www.ashresearchcollaborative.orgPending
Persistent
HTML Local Storage
ldsObjectInfo#communityApp ~ /s ~ 0DB3u000000g0P4 www.ashresearchcollaborative.orgPending
Persistent
IndexedDB
ldsObjectInfo#loginApp2 ~ /s ~ 0DB3u000000g0P4 www.ashresearchcollaborative.orgPending
Persistent
IndexedDB
oktaStateToken
American Society of HematologyPending
1 day
HTTP Cookie
phone2action-productionPhone2 Action
Pending
Session
HTTP Cookie
QCQQ
Salesforce
Pending
Session
HTTP Cookie
recordGVP51.0#communityApp ~ /s ~ 0DB3u000000g0P4 www.ashresearchcollaborative.orgPending
Persistent
IndexedDB
recordGVP51.0#loginApp2 ~ /s ~ 0DB3u000000g0P4 www.ashresearchcollaborative.orgPending
Persistent
IndexedDB
SfdcApp.projectOneNavigator:Origin www.ashresearchcollaborative.orgPending
Session
HTML Local Storage
webactls
Salesforce
Pending
Persistent
HTML Local Storage
Details
Copyright © 2024 ArchiveBay.com. All rights reserved. Terms of Use | Privacy Policy | DMCA | 2021 | Feedback | Advertising | RSS 2.0